Autophagy inhibition sensitizes KU-0063794-mediated anti-HepG2 hepatocellular carcinoma cell activity in vitro and in vivo

Biochemical and Biophysical Research Communications

Volumn 465, Issue 3, 2015, Pages 494-500

  Yongxi, Tong ^a   Haijun, Huang ^a   Jiaping, Zheng ^b   Guoliang, Shao ^b   Hongying, Pan ^a  

^a ZHEJIANG PROVINCIAL PEOPLE'S HOSPITAL   (China)

^b ZHEJIANG CANCER HOSPITAL   (China)

Author keywords

Autophagy; Hepatocellular carcinoma; KU 0063794; mTOR; Sensitization

Indexed keywords

3 METHYLADENINE; 5 [2 (2,6 DIMETHYLMORPHOLINO) 4 MORPHOLINOPYRIDO[2,3 D]PYRIMIDIN 7 YL] 2 METHOXYBENZENEMETHANOL; BAFILOMYCIN A1; BECLIN 1; CHLOROQUINE; CYCLIN D1; GREEN FLUORESCENT PROTEIN; HYPOXIA INDUCIBLE FACTOR 1ALPHA; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 2; PROTEIN P62; MORPHOLINE DERIVATIVE; MTOR PROTEIN, MOUSE; PYRIMIDINE DERIVATIVE; TARGET OF RAPAMYCIN KINASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; AUTOPHAGY; CELL ACTIVITY; CONTROLLED STUDY; DISEASE SEVERITY; DOWN REGULATION; DRUG CYTOTOXICITY; DRUG SENSITIZATION; FEMALE; GENE SILENCING; HEPG2 CELL LINE; IMMUNE DEFICIENCY; IN VITRO STUDY; IN VIVO STUDY; LIGHT CHAIN; LIVER CELL CARCINOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; RNA INTERFERENCE; TUMOR XENOGRAFT; ANIMAL; ANTAGONISTS AND INHIBITORS; CELL SURVIVAL; DOSE RESPONSE; DRUG EFFECTS; HUMAN; METABOLISM; NEOPLASMS, EXPERIMENTAL; PATHOLOGY; SCID MOUSE;

ANIMALS; APOPTOSIS; AUTOPHAGY; CELL SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; HEP G2 CELLS; HUMANS; MICE; MICE, SCID; MORPHOLINES; NEOPLASMS, EXPERIMENTAL; PYRIMIDINES; TOR SERINE-THREONINE KINASES;

EID: 84940847966     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2015.08.045     Document Type: Article

References (38)

1. R. Siegel, J. Ma, Z. Zou, and A. Jemal Cancer statistics, 2014 CA Cancer J. Clin. 64 2014 9 29
2. S. Tanaka, and S. Arii Molecular targeted therapies in hepatocellular carcinoma Semin. Oncol. 39 2012 486 492
3. S. Singh, P.P. Singh, L.R. Roberts, and W. Sanchez Chemopreventive strategies in hepatocellular carcinoma Nat. Rev. Gastroenterol. Hepatol. 11 2014 45 54
4. Y. Tong, H. Huang, and H. Pan Inhibition of MEK/ERK activation attenuates autophagy and potentiates pemetrexed-induced activity against HepG2 hepatocellular carcinoma cells Biochem. Biophys. Res. Commun. 456 2015 86 91
5. A. Villanueva, D.Y. Chiang, P. Newell, J. Peix, S. Thung, C. Alsinet, V. Tovar, S. Roayaie, B. Minguez, M. Sole, C. Battiston, S. Van Laarhoven, M.I. Fiel, A. Di Feo, Y. Hoshida, S. Yea, S. Toffanin, A. Ramos, J.A. Martignetti, V. Mazzaferro, J. Bruix, S. Waxman, M. Schwartz, M. Meyerson, S.L. Friedman, and J.M. Llovet Pivotal role of mTOR signaling in hepatocellular carcinoma Gastroenterology 135 2008 1972-1983, 1983 e1971-1911
6. J.S. Chen, Q. Wang, X.H. Fu, X.H. Huang, X.L. Chen, L.Q. Cao, L.Z. Chen, H.X. Tan, W. Li, J. Bi, and L.J. Zhang Involvement of PI3K/PTEN/AKT/mTOR pathway in invasion and metastasis in hepatocellular carcinoma: association with MMP-9 Hepatol. Res. 39 2009 177 186
7. K.D. Tang, and M.T. Ling Targeting drug-resistant prostate cancer with dual PI3K/mTOR inhibition Curr. Med. Chem. 21 2014 3048 3056
8. M. Laplante, and D.M. Sabatini mTOR signaling in growth control and disease Cell 149 2012 274 293
9. A. Gomez-Pinillos, and A.C. Ferrari mTOR signaling pathway and mTOR inhibitors in cancer therapy Hematol. Oncol. Clin. North Am. 26 2012 483 505 vii
10. K.F. Chen, P.Y. Yeh, K.H. Yeh, Y.S. Lu, S.Y. Huang, and A.L. Cheng Down-regulation of phospho-Akt is a major molecular determinant of bortezomib-induced apoptosis in hepatocellular carcinoma cells Cancer Res. 68 2008 6698 6707
11. S.Y. Sun mTOR kinase inhibitors as potential cancer therapeutic drugs Cancer Lett. 340 2013 1 8
12. E. Vilar, J. Perez-Garcia, and J. Tabernero Pushing the envelope in the mTOR pathway: the second generation of inhibitors Mol. Cancer Ther. 10 2011 395 403
13. J.M. Garcia-Martinez, J. Moran, R.G. Clarke, A. Gray, S.C. Cosulich, C.M. Chresta, and D.R. Alessi Ku-0063794 is a specific inhibitor of the mammalian target of rapamycin (mTOR) Biochem. J. 421 2009 29 42
14. H. Min, M. Xu, Z.R. Chen, J.D. Zhou, M. Huang, K. Zheng, and X.P. Zou Bortezomib induces protective autophagy through AMP-activated protein kinase activation in cultured pancreatic and colorectal cancer cells Cancer Chemother. Pharmacol. 74 2014 167 176
15. Y. Wang, C. Han, L. Lu, S. Magliato, and T. Wu Hedgehog signaling pathway regulates autophagy in human hepatocellular carcinoma cells Hepatology 58 2013 995 1010
16. B. Zheng, J.H. Mao, L. Qian, H. Zhu, D.H. Gu, X.D. Pan, F. Yi, and D.M. Ji Pre-clinical evaluation of AZD-2014, a novel mTORC1/2 dual inhibitor, against renal cell carcinoma Cancer Lett. 357 2015 468 475
17. A. Toschi, E. Lee, N. Gadir, M. Ohh, and D.A. Foster Differential dependence of hypoxia-inducible factors 1 alpha and 2 alpha on mTORC1 and mTORC2 J. Biol. Chem. 283 2008 34495 34499
18. J. Averous, B.D. Fonseca, and C.G. Proud Regulation of cyclin D1 expression by mTORC1 signaling requires eukaryotic initiation factor 4E-binding protein 1 Oncogene 27 2008 1106 1113
19. R.K. Amaravadi, and C.B. Thompson The roles of therapy-induced autophagy and necrosis in cancer treatment Clin. Cancer Res. 13 2007 7271 7279
20. D. Gozuacik, and A. Kimchi Autophagy as a cell death and tumor suppressor mechanism Oncogene 23 2004 2891 2906
21. J. Li, N. Hou, A. Faried, S. Tsutsumi, T. Takeuchi, and H. Kuwano Inhibition of autophagy by 3-MA enhances the effect of 5-FU-induced apoptosis in colon cancer cells Ann. Surg. Oncol. 16 2009 761 771
22. X.H. Liang, S. Jackson, M. Seaman, K. Brown, B. Kempkes, H. Hibshoosh, and B. Levine Induction of autophagy and inhibition of tumorigenesis by beclin 1 Nature 402 1999 672 676
23. Q.W. Fan, C. Cheng, C. Hackett, M. Feldman, B.T. Houseman, T. Nicolaides, D. Haas-Kogan, C.D. James, S.A. Oakes, J. Debnath, K.M. Shokat, and W.A. Weiss Akt and autophagy cooperate to promote survival of drug-resistant glioma Sci. Signal. 3 2010 ra81
24. J. Kim, M. Kundu, B. Viollet, and K.L. Guan AMPK and mTOR regulate autophagy through direct phosphorylation of Ulk1 Nat. Cell Biol. 13 2011 132 141
25. T. Luo, Y. Park, X. Sun, C. Liu, and B. Hu Protein misfolding, aggregation, and autophagy after brain ischemia Transl. Stroke Res. 4 2013 581 588
26. L.L. Fu, Y. Cheng, and B. Liu Beclin-1: autophagic regulator and therapeutic target in cancer Int. J. Biochem. Cell Biol. 45 2013 921 924
27. H.D. Husseinzadeh, and J.A. Garcia Therapeutic rationale for mTOR inhibition in advanced renal cell carcinoma Curr. Clin. Pharmacol. 6 2011 214 221
28. A.J. Pantuck, D.B. Seligson, T. Klatte, H. Yu, J.T. Leppert, L. Moore, T. O'Toole, J. Gibbons, A.S. Belldegrun, and R.A. Figlin Prognostic relevance of the mTOR pathway in renal cell carcinoma: implications for molecular patient selection for targeted therapy Cancer 109 2007 2257 2267
29. C.H. Jung, C.B. Jun, S.H. Ro, Y.M. Kim, N.M. Otto, J. Cao, M. Kundu, and D.H. Kim ULK-Atg13-FIP200 complexes mediate mTOR signaling to the autophagy machinery Mol. Biol. Cell 20 2009 1992 2003
30. C. Mammucari, G. Milan, V. Romanello, E. Masiero, R. Rudolf, P. Del Piccolo, S.J. Burden, R. Di Lisi, C. Sandri, J. Zhao, A.L. Goldberg, S. Schiaffino, and M. Sandri FoxO3 controls autophagy in skeletal muscle in vivo Cell Metab. 6 2007 458 471
31. S. Chen, Q. Han, X. Wang, M. Yang, Z. Zhang, P. Li, A. Chen, C. Hu, and S. Li IBP-mediated suppression of autophagy promotes growth and metastasis of breast cancer cells via activating mTORC2/Akt/FOXO3a signaling pathway Cell Death Dis. 4 2013 e842
32. S. Bialik, and A. Kimchi Autophagy and tumor suppression: recent advances in understanding the link between autophagic cell death pathways and tumor development Adv. Exp. Med. Biol. 615 2008 177 200
33. J. Reyjal, K. Cormier, and S. Turcotte Autophagy and cell death to target cancer cells: exploiting synthetic lethality as cancer therapies Adv. Exp. Med. Biol. 772 2014 167 188
34. M.V. Jain, A.M. Paczulla, T. Klonisch, F.N. Dimgba, S.B. Rao, K. Roberg, F. Schweizer, C. Lengerke, P. Davoodpour, V.R. Palicharla, S. Maddika, and M. Los Interconnections between apoptotic, autophagic and necrotic pathways: implications for cancer therapy development J. Cell Mol. Med. 17 2013 12 29
35. D.C. Rubinsztein, P. Codogno, and B. Levine Autophagy modulation as a potential therapeutic target for diverse diseases Nat. Rev. Drug Discov. 11 2012 709 730
36. L. Ouyang, Z. Shi, S. Zhao, F.T. Wang, T.T. Zhou, B. Liu, and J.K. Bao Programmed cell death pathways in cancer: a review of apoptosis, autophagy and programmed necrosis Cell Prolif. 45 2012 487 498
37. G. Spinzi, and S. Paggi Sorafenib in advanced hepatocellular carcinoma N. Engl. J. Med. 359 2008 2497 2498 author reply 2498-2499
38. J.M. Llovet, S. Ricci, V. Mazzaferro, P. Hilgard, E. Gane, J.F. Blanc, A.C. de Oliveira, A. Santoro, J.L. Raoul, A. Forner, M. Schwartz, C. Porta, S. Zeuzem, L. Bolondi, T.F. Greten, P.R. Galle, J.F. Seitz, I. Borbath, D. Haussinger, T. Giannaris, M. Shan, M. Moscovici, D. Voliotis, and J. Bruix Sorafenib in advanced hepatocellular carcinoma N. Engl. J. Med. 359 2008 378 390